argenx receives second preclinical milestone payment in collaboration with LEO Pharma
argenx SE - American Depositary Shares (ARGX)
US:NASDAQ Investor Relations:
investor.argenx.com/phoenix.zhtml?c=254223&p=irol-presentations
Company Research
Source: GlobeNewswire
June 20, 2017Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the achievement of the second of two preclinical milestones in connection with its collaboration with LEO Pharma."Our collaboration with LEO Pharma continues to be highly productive with the announcement of this most recent preclinical milestone. This achievement is the second of two success-based preclinical milestones with the first having been received last year. We continue to be excited about the potential of ARGX-112 in inflammatory skin diseases and are optimistic that the collaboration may yield a clinical program in the near future," commented Tim Van Hauwermeiren, CEO at argenx.In May 2015, argenx entered into a research collaboration and exclusive license option agreement with LEO Pharma to develop and co
Show less
Read more
Impact Snapshot
Event Time:
ARGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARGX alerts
High impacting argenx SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ARGX
News
- argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $521.00 price target on the stock.MarketBeat
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.MarketBeat
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseGlobeNewswire
- Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 [Yahoo! Finance]Yahoo! Finance
- argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.MarketBeat
ARGX
Earnings
- 2/29/24 - Miss
ARGX
Sec Filings
- 4/16/24 - Form 6-K
- 3/27/24 - Form 6-K
- 3/27/24 - Form 6-K
- ARGX's page on the SEC website